Tenoxicam
SIGMA/T0909 - NSAID
Synonym: 4-
CAS Number: 59804-37-4
Empirical Formula (Hill Notation): C13H11N3O4S2
Molecular Weight: 337.37
MDL Number: MFCD00083502
Linear Formula: C13H11N3O4S2
Product Type: Chemical
assay | ≥98% (perchloric acid titration) |
form | powder |
InChI | 1S/C13H11N3O4S2/c1-16-10( |
InChI key | LZNWYQJJBLGYLT-UHFFFAOYSA |
Quality Level | 100 ![]() |
SMILES string | O=C(NC1=NC=CC=C1)C2=C(O)C |
solubility | DMF: 25 mg/mL, clear, yellow-green |
Application: | Tenoxicam has been used: • as a non-steroidal anti-inflammatory agent (NSAID) to study its effects on root gravitropism in Arabidopsis thaliana • as a standard in microanalysis of NSAIDs by spectrophotometry • to test its effect on surface potential andmembrane fluidity modification in phosphoglyceride monolayers |
Biochem/physiol Actions: | Non-steroidal antiinflammatory drug (NSAID) with comparatively low risk of renal or hepatic toxicity. |
Biochem/physiol Actions: | Tenoxicam (TX) possesses antipyretic and analgesic effects. It elicits radical scavenging activity and has the potential to treat enkylosing spondylitis, extra-articular diseases, acute gout, and rheumatic diseases. It is also effective in treating primary dysmenorrhea, postpartum uterine contraction pain, and post-operation backaches. TX is capable of inhibiting prostaglandin synthesis. |
Packaging: | 1, 5 g in poly bottle |
Packaging: | 250 mg in poly bottle |
Symbol | ![]() |
Signal word | Danger |
Hazard statements | H301 + H311 + H331 |
Precautionary statements | P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311 |
Hazard Codes | T |
Risk Statements | 23/24/25 |
Safety Statements | 36/37/39-45 |
RIDADR | UN 2811 6.1 / PGIII |
WGK Germany | WGK 2 |
Purity | ≥98% (perchloric acid titration) |
UNSPSC | 12352202 |